These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 31505045)

  • 1. Systematic Review of l-glutamine for Prevention of Vaso-occlusive Pain Crisis in Patients with Sickle Cell Disease.
    Cieri-Hutcherson NE; Hutcherson TC; Conway-Habes EE; Burns BN; White NA
    Pharmacotherapy; 2019 Nov; 39(11):1095-1104. PubMed ID: 31505045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
    Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
    N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease.
    Weaver SB; Rungkitwattanakul D; Singh D
    J Pharm Pract; 2023 Feb; 36(1):139-148. PubMed ID: 34151636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of L-Glutamine in reducing the frequency of acute complications among patients with sickle cell disease: A randomized controlled study.
    Ebeid FSE; Aly NH; Shaheen NM; Abdellatif SMA; Okba AAM; Gad NA; Makkeyah SM
    Ann Hematol; 2024 Sep; 103(9):3493-3506. PubMed ID: 39028356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
    Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
    Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management.
    Darbari DS; Sheehan VA; Ballas SK
    Eur J Haematol; 2020 Sep; 105(3):237-246. PubMed ID: 32301178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Therapies for the Management of Pain and Vaso-Occlusive Crises in Patients With Sickle Cell Disease: A Systematic Review of Randomized Controlled Trials.
    Lowe M; Bambhroliya Z; Patel H; Patel VJ; Vudugula SA; Cheruvu NP; Raza S; Okunlola OI
    Cureus; 2023 Apr; 15(4):e38014. PubMed ID: 37223201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet agents for preventing vaso-occlusive events in people with sickle cell disease: a systematic review.
    Martí-Carvajal A; Abd El Aziz MA; Martí-Amarista C; Solà I
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):234-243. PubMed ID: 31188815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnesium for treating sickle cell disease.
    Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011358. PubMed ID: 28409830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
    Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
    Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease.
    Zaidi AU; Glaros AK; Lee S; Wang T; Bhojwani R; Morris E; Donohue B; Paulose J; Iorga ŞR; Nellesen D
    Orphanet J Rare Dis; 2021 Nov; 16(1):460. PubMed ID: 34727959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Parenteral Opioid Dosing in Adult Sickle Cell Disease Patients With Vaso-occlusive Crisis.
    Shah SP; Twilla JD; Kemp L; Phelps GL; Reaves A
    J Pain Palliat Care Pharmacother; 2018 Dec; 32(4):201-207. PubMed ID: 30896312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
    Casella JF; Barton BA; Kanter J; Black LV; Majumdar S; Inati A; Wali Y; Drachtman RA; Abboud MR; Kilinc Y; Fuh BR; Al-Khabori MK; Takemoto CM; Salman E; Sarnaik SA; Shah N; Morris CR; Keates-Baleeiro J; Raj A; Alvarez OA; Hsu LL; Thompson AA; Sisler IY; Pace BS; Noronha SA; Lasky JL; de Julian EC; Godder K; Thornburg CD; Kamberos NL; Nuss R; Marsh AM; Owen WC; Schaefer A; Tebbi CK; Chantrain CF; Cohen DE; Karakas Z; Piccone CM; George A; Fixler JM; Singleton TC; Moulton T; Quinn CT; de Castro Lobo CL; Almomen AM; Goyal-Khemka M; Maes P; Emanuele M; Gorney RT; Padgett CS; Parsley E; Kronsberg SS; Kato GJ; Gladwin MT
    JAMA; 2021 Apr; 325(15):1513-1523. PubMed ID: 33877274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar's healthcare perspective.
    Adel AM; Abushanab D; Al-Badriyeh D; Hamad A; Alshurafa A; Yassin MA
    SAGE Open Med; 2024; 12():20503121231224551. PubMed ID: 38711465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of patient-reported vaso-occlusive crisis day as an endpoint in sickle cell disease studies.
    Coyne KS; Currie BM; Callaghan M; Wyrwich KW; Pease S; Baker CL; Arkin S; Pittman DD
    Eur J Haematol; 2022 Sep; 109(3):226-237. PubMed ID: 35569114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial.
    Orringer EP; Casella JF; Ataga KI; Koshy M; Adams-Graves P; Luchtman-Jones L; Wun T; Watanabe M; Shafer F; Kutlar A; Abboud M; Steinberg M; Adler B; Swerdlow P; Terregino C; Saccente S; Files B; Ballas S; Brown R; Wojtowicz-Praga S; Grindel JM
    JAMA; 2001 Nov; 286(17):2099-106. PubMed ID: 11694150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sickle cell disease complications: Prevalence and resource utilization.
    Shah N; Bhor M; Xie L; Paulose J; Yuce H
    PLoS One; 2019; 14(7):e0214355. PubMed ID: 31276525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome.
    Morris CR; Kuypers FA; Larkin S; Vichinsky EP; Styles LA
    J Pediatr Hematol Oncol; 2000; 22(6):515-20. PubMed ID: 11132219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancements in Sickle Cell Disease (SCD) Treatment: A Review of Novel Pharmacotherapies and Their Impact on Patient Outcomes.
    Khan SJ; Zaidi SAT; Murtaza SF; Asif M; Kumar V
    Cureus; 2023 Aug; 15(8):e42847. PubMed ID: 37664319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.